Insider · CIK 0001674905
Sonja Nelson
Files at MOTS (Motus GI Holdings, Inc.), AMAM (Ambrx Biopharma, Inc.). First filing Oct 31, 2023, latest Oct 31, 2023.
In brief
Sonja Nelson files SEC Form 4 as CFO and director at AMAM (Ambrx Biopharma, Inc.), and also at MOTS (Motus GI Holdings, Inc.). Since Oct 31, 2023, Sonja Nelson has reported 0 open-market buys worth $0 and 1 open-market sell worth $125k, the latest filed on Oct 31, 2023.
A track record needs three past buys with six months of prices behind them; Sonja Nelson has 0, so none is measured yet.
The newest scored trade: sold $125k of AMAM on Oct 27, 2023, filed Oct 31, 2023, scored 21 (weak), under a 10b5-1 plan.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Ambrx Biopharma, Inc. | $125k 12,778 shares | -9% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 27, 2023 | Ambrx Biopharma, Inc. | 12,778 0.02% of outstanding | $125k | Oct 27, 2023 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2024 | MOTS Motus GI Holdings, Inc. | AGrant or award Stock Option (right to buy)derivative | +23,205 | $0.00 | $0 | 23,205 | Mar 13, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Common Stock | -22,936 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -107,143 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -50,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -367,799 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -121,427 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -60,714 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | AMAM Ambrx Biopharma, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -55,571 | - | - | 0 | Mar 7, 2024 |
| Dec 11, 2023 | AMAM Ambrx Biopharma, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 545,776 | Dec 11, 2023 |
| Oct 27, 2023 | AMAM Ambrx Biopharma, Inc. | SOpen-market sale Common Stock10b5-1 | -12,778 | $9.82 | $125k | 130,079 | Oct 31, 2023 |
Questions about Sonja Nelson
Answered from the filings on this page, as of the latest one.
Is Sonja Nelson buying or selling?
Not in the last 12 months. Sonja Nelson's latest open-market trade on SEC Form 4 was sold $125k of AMAM on Oct 27, 2023.
How did Sonja Nelson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sonja Nelson has 0.
Where does Sonja Nelson file Form 4?
Sonja Nelson has filed Form 4 at AMAM (Ambrx Biopharma, Inc.) as Chief Financial Officer; MOTS (Motus GI Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.